Evolving Evidence and Treatment Strategies in Low Grade Serous Ovarian Cancer (LGSOC)
Activity Overview
The GOG Foundation, Inc. and GOG Partners welcome gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to attend the Evolving Evidence and Treatment Strategies in Low Grade Serous Ovarian Cancer (LGSOC) Industry Supported Symposium being presented at the WAGO 2026 Annual Meeting on Friday, June 19, 2026 from 12:20 pm – 1:50 pm in Denver, Colorado.
Course Description
This program provides an in‑depth review of the evolving treatment landscape for patients with low grade serous ovarian cancer (LGSOC) with a focus on emerging science and practical application in patient care. Participants will explore the competitive landscape, new indications, and emerging therapies (including the role of antibody–drug conjugates, and other novel strategies). The course will also address the management of adverse events, dose modifications, and strategies to mitigate treatment‑related reactions. A discussion of biomarkers and how they may impact choices for first- and second-line therapies will help clinicians make informed, evidence‑based decisions.
The GOG Foundation, Inc. is grateful for our commercial supporter for this symposium: Verastem Oncology
Target Audience
Gynecologic and medical oncologists, oncology researchers, clinical trial coordinators, advanced practice providers, and other healthcare professionals involved in the management of ovarian cancer.
Learning Objectives
Upon completion of the activities in this series, learners will demonstrate increased knowledge regarding:
- To understand the current competitive landscape and new indications in the first line and second line setting
- To evaluate the current use of biomarker testing in the disposition to specific therapies
- To introduce emerging therapies including the future of antibody drug conjugates (ADCs) and CDK 4/6 inhibitors in LGSOC
- To educate on how to manage adverse events and mitigation strategies to prevent adverse events from occurring
Moderator
Faculty
Agenda
Evolving Evidence and Treatment Strategies in Low Grade Serous Ovarian Cancer (LGSOC), an Industry Supported Symposium presented at the WAGO 2026 Annual Meeting
Thomas Herzog, MD, University of Cincinnati
Dana Chase, MD, UCLA School of Medicine
Krish Tewari, MD, University of Calfornia, Irvine, Chao Family Comprehensive Cancer Center
All Faculty
All Faculty
Continuing Education
In support of improving patient care, this activity has been planned and implemented by The GOG Foundation, Inc. (GOG).
Accreditation Statement
The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.
The GOG Foundation, Inc. designates this in-person activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. Participants must: 1) read the educational objectives and faculty disclosures; 2) attend the educational activity; 3) complete the online evaluation that will be sent to all registered participants who provide a valid email address and attend the activity.
Participants who complete the educational activity and evaluation will receive a certificate of credit.
In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations. All relevant financial relationships listed for these individuals have been mitigated to ensure a bias-free presentation. Please see the faculty disclosure list for detailed information.
Faculty Disclosures
- Katherine Fuh, MD, PhD, University of California San Francisco (UCSF), San Francisco, CA
- Christine Walsh, MD, University of Colorado Hospital, Anschutz Cancer Pavilion
- Shannon Westin, MD, MD Anderson Cancer Center